Bill Ackman

Bill Ackman

Last Update: 2014-11-21

Number of Stocks: 7
Number of New Stocks: 1

Total Value: $13,426 Mil
Q/Q Turnover: 2%

Countries: USA
Details: Top Buys | Top Sales | Top Holdings  Embed:

Bill Ackman Watch

  • Ackman’s Pershing Square Buys Stake in Zoetis

    Zoetis, Inc. (NYSE: ZTS) is an animal health company that produces vaccines for pets and livestock. Based in Florham Park, New Jersey, the animal health company was once a subsidiary of Pfizer (PFE) but became independent in February 2013. Bill Ackman (Trades, Portfolio), the philanthropic founder and CEO of Pershing Square Capital Management, bought an 8.5% stake in Zoetis for roughly $2 billion on November 11. Additionally, Zoetis released its third quarter report on November 4, topping analysts' expectations.


    Highlights from the Q3 report include a reported $0.41 earnings per share on an adjusted diluted basis, a 21% year-over-year increase. This figure beat the analyst consensus of $0.37 by $0.04. Revenue for the third quarter met the analyst estimate of $1.2 billion; a 10% year-over-year increase. CEO Juan Ramón Alaix attributed the performance to “13% operational revenue growth in our livestock products and continued discipline around our operating expenses.”

      


  • Bob Olstein On 'Boring' Stocks Printing Money

    Bob Olstein, chairman and CIO of Olstein Funds, is known  as one of the leading experts in corporate disclosure and reporting practices. He wrote an incredible book, The Quality of Earnings, which helped push the use of forensic accounting techniques to identify certain factors in determining a company's future earnings power. (I highly recommend this book.)


    Olstein gives his take on "boring" stocks and how much money they can make in free cash flow. This will translate into investment returns over time.

      


  • Activist Bill Ackman Buys Big Stake In Animal Healthcare Company Zoetis

    I guess we shouldn’t be surprised that one of the more active activist investors is making another big move before the end of the year.


    Pershing Square, of which renowned investor Bill Ackman (Trades, Portfolio) Manages, has accumulated a stake in Zoetis Inc (ZTS) of roughly 10%. He is joined by Scott Ferguson (former protégé of Ackman), of Sachem Head Capital in this activist campaign. Sachem will consult with Ackman and Pershing.

      


  • Bill Ackman's New Interview With Bloomberg

    Summany Of Bill Ackman's (Trades, Portfolio) Interview With Bloomberg


    Bill Ackman (Trades, Portfolio) of Pershing Square Capital did a interivew with Bloomberg's Hans Nickols from the Euronext Amsterdam, where he took Pershing Square Holding public. In the interview, he talks about the the money that the company raised, and how he is preparing to "buy a decent-sized stake in a U.S. company." Ackman goes into detail about some of his holdings in Allergan (AGN), Herbalife (HLF) and Fannie (FNMA) and Freddie (FMCC). Ackman comfirms that he has in the last week increased his stakes in Fannie and Freddie by at least 20%. Also, Pershing Square isn't reporting its holdings of Fannie and Freddie anymore, since Fannie and Freddie only make up 2.5% of the firm's capital base.

      


  • Bill Ackman Discusses Herbalife and His New Investment Vehicle

    From his newly-listed Amsterdam investment vehicle, Bill Ackman (Trades, Portfolio) has $6 billion in cash and already knows where he is going to investment.


    The target? A single, yet-to-be-named U.S. company.

      


  • Ackman's Pershing Square Now Available To The Public

    Bill Ackman’s Pershing Square Holdings started trading on the Euronext Amsterdam under the symbol “PSH” on October 13. Daniel Loeb had a similar IPO in 2007 on the London Stock Exchange with his fund, Third Point Offshore (LSE:TPOU, LSE:TPOG, TPNTF). The goal of the IPO is to raise permanent capital to help the activist investor maintain his positions in target companies during times of turbulence. If too many investors have redemption requests in the hedge fund, the manager will not be able to maintain a position of control over all of the companies in the portfolio.


    Pershing Square was listed on the exchange in Amsterdam because funds that have an incentive fee as part of its expense to shareholders cannot be publically listed in the United States. Typically, hedge funds will charge a flat fee plus a percentage of the profits. The fund can trade in the U.S. through the OTC market if the fund is outside of the country and trading primarily on a foreign exchange. Pershing Square Holdings, Ltd. is incorporated under the laws of Guernsey. Originally, Ackman was considering a listing on the London Stock Exchange, but it would have been listed in the Specialist Fund Market. Being listed on the Euronext Amsterdam exchange provides more liquidity. The fund is currently only available on the Amsterdam exchange, and it is uncertain as to when it will be available OTC in the U.S.

      


  • Bill Ackman's Midas Touch

    Outside the investment community, the name of Bill Ackman (Trades, Portfolio) of Pershing Square might not raise as many eyebrows as the name of a guru like Warren Buffett (Trades, Portfolio), but Ackman’s track record is still impressive. He seems to have the Midas touch, even more of one than many of the gurus followed by GuruFocus.


    Ackman founded New York-based Pershing Square in 2004. So far in 2014, Pershing has gained 31.5%, including a 1.4% increase in September, a time when many of Ackman’s peers struggled. As GuruFocus pointed out in August, Pershing’s gain is “well above the 2.5% hedge-fund industry average.”

      


  • Bill Ackman and Valeant Could Sweeten Allergan Deal By $15 A Share

    Bill Ackman (Trades, Portfolio) Pershing Square Capital and Valeant Pharmaceutical (VRX) are said to be planning to boost their offer to acquire Botox maker Allergan (AGN) by $15 a share. The enhancement offer marks the third increase to the original bid by Bill Ackman (Trades, Portfolio)'s Pershing Square Capital and Valeant. The latest increase in the bid is intended to keep Allergan from striking a rival deal. The bid by Pershing Square and Valeant could potenitally value Allergan at over $56 billion and if the duo's can it the deal with Allegan then the merger will be the largest of the year so far.


    Earlier Allergan called a truce with Pershing Square and Valeant by reaching a aggreement over a special shareholder meet that was originally scheduled date of Dec. 18. All shareholders of Allergan record on Oct. 30 will be entitled to receive a notices and vote at the Dec. 18 meeting. The plan to raise the price by $15 more dollars a share is to drive event driven hedge funds and other investors to invest in a the share before Oct. 30 so they can vote at the meeting on Dec. 18. The plan is to oust a majority of Allergan board of directors to make way for merger talks that the current board rebuffed.

      


  • Pershing Square Plans a $2 Billion Amsterdam Fund Public Listing

    Activist fund manager Bill Ackman (Trades, Portfolio), founder of Pershing Square, hopes to raise at least $5 billion from institutional investors who aren't in the United States. His Pershing Square Capital Management is preparing for a public listing on the Amsterdam Stock Exchange. There are reports that the firm has already raised $1.5 billion from 30 of its core investors and currently have 300 investors.


    The Fund will be called Pershing Square Holdings and reuters has reported that USB and Deutsche Bank will underwriting the listing. The fund so far this year has gained 31.2 percent in returns on investments and the the fund has currently net asset value of $2.9 billion. The firm expects its shares to start trading on Cctober 13 at a price of $25 per share. Pershing Square plans on investing $100 million into the fund, and this will be separate from itself. The firm hope that Pershing Square Holdings will after completing the IPO will have at least or more than a market capitalization of $5 billion.

      


  • Hedge Fund Manager Bill Ackman with a Very Profitable Year

    In this article, let´s take a look at Bill Ackman (Trades, Portfolio), the man who is the founder and CEO of Pershing Square Capital Management LP, the hedge fund that has gained about 30% this year, well above the 2.5% hedge-fund industry average.


    Ackman, who considers himself an activist investor, pushes for management change to boost stock prices. Let`s see some of his favorites stakes.

      


  • Bill Ackman Is Preparing For The Next Crash

    In Pershing Square’s quarterly newsletter released yesterday, August 13, Bill Ackman stated that he is planning an initial public offering of Pershing Square Holdings, Ltd targeted for later this year. The plan is for the closed-end fund to be listed on the London Stock Exchange under the symbol “PSH.”


    The reason for the IPO is to help alleviate the risk of investor redemptions. In the letter, Ackman said the following about redemptions:

      


  • How Investors Could Profit From the Pershing Square Versus Herbalife Duel

    Disclosure: I neither long nor short Herbalife. I also do not have any financial interest in the company.


    What is the Recent Story On Herbalife

      


  • Ackman Explains Valeant Bid, Makes Up with Carl Icahn



  • Bill Ackman Continues Diatribe Against Herbalife



  • Bill Ackman's New REITs

    Pershing Square's Bill Ackman (Trades, Portfolio) finally jettisoned the remainder of one of his largest activist positions, the real estate investment trust (REIT) General Growth Properties (GGP) – a four-year project – in the first quarter. Though he ventured into the real estate space before, with holdings in Howard Hughes Corp (HHC) (current position) and Alexander & Baldwin Inc. (ALEX) (sold fourth quarter 2012), in the first quarter as he sold out General Growth, he added more exposure to REITs – known for their high dividend payments – with the acquisition of Apartment Investment & Management Company (AIV) (or Aimco) and Home Properties Inc. (HME).

    Aimco was Ackman’s second largest new first quarter position, behind Platform Specialty Products Corp (PAH). With 3,749,393 shares, the position reflects 1.4% of his long portfolio, of 2.57% of the company’s outstanding shares. The first quarter average share price of the company was $29, for a transaction value around $108.7 million – small in comparison to the over half a billion he spent on Platform Specialty.  


  • Activist Bill Ackman's First Quarter Top Positions

    Bill Ackman (Trades, Portfolio), the controversial activist leader of Pershing Square Capital Management, released his first quarter holdings yesterday. These holdings highlighted nine stocks, with four of these being new buys over the quarter. His portfolio is valued at $8.4 billion.


    The following five companies are the five stocks Ackman holds the most of his portfolio in. The guru’s top five positions make up for approximately 88% of his total portfolio.

      


  • Bill Ackman Freddie Mac and Fannie Mae Ira Sohn Presentation

    <p style=" margin: 12px auto 6px auto; font-family: Helvetica,Arial,Sans-serif; font-style: normal; font-variant: normal; font-weight: normal; font-size: 14px; line-height: normal; font-size-adjust: none; font-stretch: normal; -x-system-font: none; display: block;"> Bill Ackman Ira Sohn Freddie Mac and Fannie Mae Presentation

      


  • Bill Ackman Interview: Forgiving Icahn, Valeant Merger, Fannie Mae and Freddie Mac



  • Bill Ackman and Valeant Pharmaceuticals Team Up to Take Over Pharmaceutical Company Allergen

    Over the past week GuruFocus Real Time Picks reported that Bill Ackman (Trades, Portfolio) made a buy into Allergen (AGN). This is the first buy into the company for Ackman, and he did so in a big way by purchasing a total of 28,878,538 shares of the company’s stock. He bought these shares at the average price of $120.89 per share on April 11, and since this buy the price per share is up 35% to $163.65.


    Ackman’s Pershing Square Capital Management has taken a near 10% stake in Allergan over the past couple of months. The fund has now teamed up with the Canadian-based Valeant Pharmaceuticals International (VRX) which is known for its consistent track record in acquiring other companies. Ackman’s activist fund and Valeant have partnered together to purchase Allergan for roughly $46 billion in a cash-and-stock deal, according to Bloomberg.

      


  • Bill Ackman Discusses Valeant on CNBC



Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

Gm1
ReplyGm1 - 2 months ago
Dear Sirs / Madams,

I am so interested in Pershing Square, would you please advise me its performance and cost? Thank you.

GM
Samchell@yahoo
ReplySamchell@yahoo - 7 months ago
Some stocks are best evaluated by hands-on personal empiricism. After going into a Walgreen's store, it's manifestly clear where it ranks compared to CVS or Rite Aid. As for Ackman's attraction to Mondelez, perhaps he likes some of the company's snack items, and no doubt enough other consumers will share his taste to move the stock in a positive direction. But anyone looking for more something more dramatic would be better advised to take note of the population's compulsive consumption of Hershey products. (Twizzler's Twist 'n Pull Cherry Licorice is candy heroin.) Also, like Coke and Kleenex, Hershey's is a brand name that's synonymous with the product. (When's the last time your spouse asked you to go to Walgreen's to pick up a "Mondelez Bar"?) In short, investing is a game of guessing, supported by past predilections and indicators that "may" have a bearing on future results. But 50% of stock picking is playing hunches. Never ignore the intangibles as well as personal impressions--that's can't be charted or measured by most systems.



Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK